What is Neurapheresis™ Therapy?
The Neurapheresis™ Cerebrospinal Fluid (CSF) Treatment Platform is being developed to provide a safe, device-based alternative for treating debilitating and life-threatening diseases that involve foreign bodies in the cerebrospinal fluid.
The current Neurapheresis platform offers a tailored process for the treatment and return of cerebrospinal fluid. Neurapheresis Therapy in post-subarachnoid hemorrhage (aSAH) patients is presently being utilized in the PILLAR XT Study in the US*. The trial is intended to rapidly remove red blood cells (RBCs) and hemoglobin from the CSF shortly after SAH securement. The removal of RBCs and their released cytotoxic byproducts may be accomplished much more efficiently with Neurapheresis therapy, than with standard gravity-dependent drains. It is theorized that early, rapid removal of RBCs post-SAH may reduce downstream complications including the incidence of hydrocephalus, cerebral vasospasm, and contribute to a shorter length of stay, lower healthcare resource utilization, improved clinical functional outcomes, and a reduced overall healthcare economic burden.1,2,3
1 Panni P, Fugate JE, Rabinstein AA, Lanzino G. Lumbar drainage and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review. J Neurosurg Sci. 2017 Dec;61(6):665-672.
2 Borkar SA, Singh M, Kale SS, et al. Spinal cerebrospinal fluid drainage for prevention of vasospasm in aneurysmal subarachnoid hemorrhage: a prospective, randomized controlled study. Asian J Neurosurg. 2018;13(2):238-246.
3 Klimo P Jr, Kestle JR, MacDonald JD, Schmidt RH. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg. 2004 Feb;100(2):215-24.
*Research supported by the National Institute Of Neurological Disorders And Stroke of the National Institutes of Health under Award Number R44NS110247